key: cord-0980124-kfsf4qrf
authors: Bozgeyik, Ibrahim
title: Therapeutic potential of miRNAs targeting SARS-CoV-2 host cell receptor ACE2
date: 2020-11-18
journal: Meta Gene
DOI: 10.1016/j.mgene.2020.100831
sha: 0e91b0af062295179da81a362a4d8a405f294fe9
doc_id: 980124
cord_uid: kfsf4qrf

In late December 2019, several cases of pneumonia of unknown etiology (COVID-19) were reported in Wuhan, Hubei province, China. Based on clinical findings, blood tests and chest radiographs, this disease was diagnosed as a virus-associated pneumonia. Sequence analysis revealed a novel coronavirus, called SARS-CoV-2 (formerly called 2019-nCoV), as the causative agent of pneumonia of unknown etiology. So far, the SARS-CoV-2 infection continues to spread, and this virus poses a serious public health threat. In this study, it was aimed to reveal potential miRNA targets for the regulation of SARS-CoV-2 host cell receptor ACE2. For the identification of potential miRNA targets for the ACE2 gene, TarBase v.8 (DIANA Tools), TargetScan, miRTarBase and miRDB miRNA-target prediction algorithms were used. FANTOM5 CAGE was used for the cellular ontology analysis. Expression levels of these miRNAs were determined using OncomiR Pan-Cancer miRNome Atlas. The results suggest that members of miR-200 family of miRNAs, especially miR-200c-3p, are strong candidate targets for the regulation of ACE2 in respiratory system cells. Consequently, the present study for the first time emphasizes potential use of miRNA-based therapeutics in the battle against SARS-CoV-2 infection and its deadly disease, COVID-19.

Since the emergence of the novel coronavirus disease in December 2019 in Wuhan, China (Chen and Wang, 2020) , the situation has rapidly evolved to a global health problem. The outbreak was announced as a Public Health Emergency of International Concern (PHEIC) on January 30, 2020 and declared as a pandemic on March 11, 2020 by World Health Organization (WHO) (https://www.who.int/news-room/detail/27-04-2020-who-timeline--covid-19). Corona Virus , the illness caused by the SARS-CoV-2 (formerly called 2019-novel coronavirus (2019-nCoV)) infection, is out of control worldwide.

Although a significant number of individuals infected with the SARS-CoV-2 remain asymptomatic and unrecognized, infected patients typically develop pneumonia which may lead to severe complications such as acute respiratory distress syndrome and multiple organ failure. So far, significant number of adults and children were affected from this disease and pandemic continues to spread widely and rapidly across the world (Rathore et al., 2020; Sacco et al., 2020) . As of October 27, 2020, a total of 43,561,060 confirmed cases of COVID-19 and 1,160,389 deaths have been reported globally (https://coronavirus.jhu.edu/map.html). Elderly people and individuals with co-existing respiratory or cardiovascular manifestations appear to be at higher risk of developing severe complications of COVID-19. At present, only supportive care such as oxygen therapy and treatment with antibiotics, is provided to the patients. Some off-label therapies such as certain licensed anti-viral drugs, anti-inflammatory and anti-parasitic agents, and convalescent plasma, are currently used to manage the disease.

However, currently, there is no approved effective medication or vaccine available for the treatment of disease caused by the SARS-CoV-2 infection because of lack of evidence. Due to the lack of specific antiviral treatments and insufficient clinical treatments available, virusrelated death rates are increasing worldwide.

Moreover, microRNAs (miRNAs) are small regulatory RNA molecules with an average length of 22 nucleotides and do not code for proteins, instead, code for functional RNA molecules for regulatory purposes and control gene expression at post-transcriptional level (Ambros, 2004; Bartel, 2018) . Accumulating evidence suggest that miRNAs play chief roles in the regulating of vital cellular processes such as growth, proliferation, differentiation and apoptosis. Deregulation of microRNA expression has been shown to significantly contribute to the development and progression of many diseases, especially cancer, diabetes, immune system diseases and neurodegenerative diseases. Accordingly, in the present study, it was aimed to reveal potential miRNA targets for the regulation of SARS-CoV-2 host cell receptor ACE2.

TarBase v.8 (DIANA Tools) (Karagkouni et al., 2018) , TargetScan(Agarwal et al., 2015) , miRTarBase(Chou et al., 2018) and miRDB(Chen and Wang, 2020) miRNA-target prediction algorithms were used to predict potential miRNAs targeting ACE2 (Angiotensin I converting enzyme 2) gene. In screening of miRNAs targeting ACE2 gene, either gene symbol "ACE2", Ensembl ID or 3'UTR sequence were used.

For the determination of validated miRNA targets of ACE2, a literature search with the keywords "ACE2", "miRNA", "microRNA", "Angiotensin-converting enzyme 2" in PubMed, Google Scholar, ScienceDirect platforms were performed. Publications until 20 May 2020 were evaluated and miRNAs involved in the direct regulation of ACE2 were listed (Table 1) .

Expression of miRNAs, either experimentally validated or predicted to target ACE2, were (Wong et al., 2018) . The expression level of 4 of the 5 miRNAs associated with ACE2 were available.

To identify, miRNAs targeting host cell receptor ACE2, miRNA target prediction algorithms were used and several miRNAs targeting ACE2 receptor were identified. miRNAs have previously shown to be involved in the regulation of ACE2 receptor, but not predicted to target ACE2 in these databases, were also identified from previous experimental evidences. A total of 24 miRNAs (miR-1208, miR-4318, miR-4314, miR-302c, miR-329, miR-501, miR-655, miR-584, miR-574, miR-383, miR-125b, miR-1915, miR-513b, miR-1303, miR-760, miR-3934, miR-136, miR-218, miR-1251, miR-500a, miR-500b, miR-200a, miR-200b, and miR-200c) . miR-200b and miR-200c were found to be highly conserved ( Figure 1A ). Binding positions of miR-200c-3p and miR-200b-3p with ACE2 was also presented using the TargetScan algorithm ( Figure 1B) . Furthermore, cellular ontologies of these miRNAs were also evaluated. miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-210-3p and miR-429 were found to be highly enriched in respiratory epithelial cells (Supp. Fig 1) . In addition, cellular ontologies these miRNAs in other body cells were also presented in Table 2 . The expression levels of these miRNAs using OncomiR algorithm in Lung adenocarcinoma (LUAD) and

Lung squamous cell carcinoma (LUSC) samples were also analyzed (Supp. Fig 2) . Also, using target correlation interface, miRNAs potentially target ACE2 were determined. It was found that miR-200c-3p is the only target miRNA that regulate ACE2 in cancer cells.

Consistently, a significant negative correlation was identified between ACE2 and miR-200c-3p (Correlation coefficient: -0.2910, p=7.86e-26) in all types of cancer. Also, correlation false discovery rate (FDR) was highly low in all types of cancers (correlation FDR=1.15e-24).

One of the first antisense oligonucleotide to enter clinical trials was the locked nucleic acid (LNA-)-modified oligonucleotide complementary to 5ʹ end of miR-122 (miravirsen) for the treatment of HCV. Recently, a phase IIa clinical trial was initiated for the examination of long-term efficacy and safety of miravirsen in patients with chronic HCV genotype 1 infection (Rupaimoole and Slack, 2017) . Unlike widely known functions of miRNAs in gene silencing, miR-122 advances the HCV replication thorough binding 5ʹ non-coding regions of the HCV RNA genome (Jopling et al., 2005) . Binding of the miR-122 to 5ʹ non-coding J o u r n a l P r e -p r o o f regions of the HCV viral genome increases its stability in which viral RNA genome acts as a miRNA sponge for miR-122, leading to a reduction in miR-122 abundance at the site of infection and deregulation of liver homeostasis. Studies showed binding of miR-122 serves as a 5ʹ cap and protect viral RNA genome against Xrn1 exoribonuclease -mediated cleavage (Thibault et al., 2015) .

In the light of the miR-122 story in HCV replication, we would also benefit miRNA therapeutics targeting SARS-CoV-2 host cell receptor ACE2. Herein, it was demonstrated that members of miR-200 family of miRNAs, especially miR-200c-3p, are strong candidate targets for the regulation of ACE2 in respiratory system cells. It was also identified that several other miRNA targets for the post-transcriptional regulation of ACE2 cells. Our results suggest that human encoded miRNAs could be the finest candidates for development of miRNA-based therapeutics in the management of SARS-CoV-2 infection. Studies can also focus on the miRNAs directly targeting genomic RNA of SARS-CoV-2. Although it is difficult to make a definitive judgment with the present data, it is evident that findings obtained in the present study will guide future studies in the fight against SARS-CoV-2 infection and enable identification of miRNA targets for antiviral intervention. More recently, it has been suggested that SARS-CoV-2 genome can be targeted by combination of several miRNAs (El-Nabi et al., 2020) . It has also been suggested that miRNAs targeting SARS-CoV-2 genome can be delivered using more suitable patient-friendly, high-efficacy delivery systems such as polymer-based carriers, liposome-like exosomes, or inorganic nanoparticles (El-Nabi et al., 2020) .

As the pandemic continues to spread, identification and developing drug targets with highefficacy targeting SARS-CoV-2 infection is of great interest. This deadly disease is currently responsible from the death of more than a million people. In the present study, using a bioinformatic approach, several members of the miR-200 family of miRNAs were identified to be good candidates for targeting SARS-CoV-2 host cell receptor ACE2. However, through the miR-18a/Nox2/ROS pathway. Journal of cellular and molecular medicine 22, 1873-1882. Zhang, R., Su, H., Ma, X., Xu, X., Liang, L., Ma, G. and Shi, L., 2019. MiRNA let-7b promotes the development of hypoxic pulmonary hypertension by targeting ACE2. American Journal of Physiology-Lung Cellular and Molecular Physiology 316, L547-L557. 

DIANA-TarBase v8: a decade-long collection of experimentally supported miRNAgene interactions

MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy

Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421

Role of signaling pathway of long noncoding RNA growth arrest-specific transcript 5/microRNA-200c-3p/angiotensin converting enzyme 2 in the apoptosis of human lung epithelial cell A549 in acute respiratory distress syndrome

miRNA-200c-3p is crucial in acute respiratory distress syndrome

Differences in miR29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy

Update of the FANTOM web resource: expansion to provide additional transcriptome atlases

MicroRNome analysis unravels the molecular basis of SARS infection in bronchoalveolar stem cells

COVID-19 Pandemic and Children: A Review

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

Symptoms of COVID-19 among older adults: systematic review of biomedical literature

Mir-21 mediates the inhibitory effect of Ang (1-7) on AngII-induced NLRP3 inflammasome activation by targeting Spry1 in lung fibroblasts

Regulation of hepatitis C virus genome replication by Xrn1 and microRNA-122 binding to individual sites in the 5′ untranslated region

Circulating miR-421 targeting leucocytic angiotensin converting enzyme 2 is elevated in patients with chronic kidney disease

OncomiR: an online resource for exploring pan-cancer microRNA dysregulation

ACE2-EPC-EXs protect ageing ECs against hypoxia/reoxygenation-induced injury

 (Liu et al., 2017) Let-7bHypoxic Pulmonary Hypertension  (Zhang et al., 2019) J o u r n a l P r e -p r o o f